News

Phase 1b Trial Begins Testing NKTR-358 in SLE Patients

The Phase 1b trial evaluating NKTR-358 — an investigational therapy that stimulates regulatory T-cell activation — in systemic lupus erythematosus (SLE) has begun dosing patients, Nektar Therapeutics announced. Unlike immunosuppressive therapies that dampen the entire immune system, and are associated with potentially serious side effects, NKTR-358 was designed to restore the…